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Glucocorticoids acting through the glucocorticoid receptor (GR) inhibit TNF-induced lethal inflammation. 
Here, we demonstrate that GR dimerization plays a role in reducing TNF sensitivity. In mutant mice unable to 
dimerize GR, we found that TNF failed to induce MAPK phosphatase 1 (MKP1). We assessed TNF sensitivity 
in Mkp1–/– mice and found increased inflammatory gene induction in livers, increased circulating cytokines, 
cell death in intestinal epithelium, severe intestinal inflammation, hypothermia, and death. Mkp1–/– mice 
had increased levels of phosphorylated JNK, which promotes apoptosis, in liver tissue. We further examined 
JNK-deficient mice for their response to TNF. Although Jnk1–/– mice showed no change in sensitivity to TNF, 
Jnk2–/– mice were significantly protected against TNF, identifying JNK2 as an essential player in inflamma-
tion induced by TNF. Furthermore, we found that loss of Jnk2 partially rescued the increased sensitivity of 
Mkp1–/– and mutant GR mice to TNF. Our data show that GR dimerization inhibits JNK2 through MKP1 and 
protects from TNF-induced apoptosis and lethal inflammation.
Introduction
TNF plays an important role in inflammatory disorders such as 
rheumatoid arthritis, inflammatory bowel disease (IBD), and pso-
riasis (1, 2). Biological drugs that inhibit TNF are effective, despite 
some limited side effects (3). However, the mechanism by which 
TNF activates and sustains the inflammatory response is not yet 
clear. TNF induces transcription factors, such as NF-κB and AP-1, 
that stimulate the expression of hundreds of genes, activate cell 
death, and cause tissue damage (4). Clinical and animal studies 
have identified hypotension, liver toxicity, and bowel necrosis as 
the major determinants of TNF lethality (5).
Both exogenous and endogenous glucocorticoids (GCs) protect 
against TNF-induced lethal inflammation (6, 7). The binding of 
GCs to the GC receptor (GR) protects against TNF lethality, as 
shown by the use of GR blockers and GR-deficient mice (8, 9). 
However, the protective mechanism is not fully elucidated. GC-acti-
vated GR can form dimers, which bind to GC response elements 
(GREs) (1) and lead to transactivation (TA) of metabolic and anti-
inflammatory genes. GR can also transrepress genes by binding 
as a monomer to transcription factors such as NF-κB and AP-1 
(10, 11). It has been proposed that the antiinflammatory effects 
of GR are mainly mediated by transrepression (TR) and that the 
induction of unwanted side effects of GC therapy (such as type 2 
diabetes) is mediated by TA. Therefore, researchers have been devel-
oping ligands that favor GR monomers (12, 13). However, several 
transactivated genes that have been identified encode strong anti-
inflammatory molecules, such as MKP1 (14, 15). MKP1 (encoded 
by Mkp1; also known as dual-specificity phosphatase-1, Dusp1) is a 
member of the family of dual-specificity phosphatases, which pref-
erentially dephosphorylate MAPKs, such as p38 and JNK (16). Since 
these MAPKs are essential in the initiation of inflammation, MKP1 
has been described as critical for the resolution of inflammation. 
Indeed, Mkp1–/– mice are very sensitive in models of endotoxemia, 
sepsis, and other inflammatory diseases (17–19).
To identify the protective mechanism of endogenous GCs and 
GR, we here used mice expressing a mutant version of the GR pro-
tein, namely GRdim/dim. This mutant protein carries a single point 
mutation (A458T) that prevents it from forming dimers (20, 21). 
Hence, GRdim/dim mice are largely devoid of TA induced by GR 
dimers and are more sensitive to inflammatory diseases, such as 
contact hypersensitivity and sepsis (22, 23). These findings indi-
cate that at least 1 GRE gene is induced by GR and has antiinflam-
matory functions in the GRdim/dim model, and perhaps in other 
models and diseases as well.
In this work, we used GRdim/dim mice to study the contribu-
tion of GRE genes to the protection against the lethal effects 
of TNF. We concluded that endogenous GCs protected against 
TNF lethality in a GR dimer–dependent manner. This protection 
specifically involved MKP1-mediated dephosphorylation of the 
proapoptotic JNK2 MAPK (24, 25).
Results
GRdim/dim mice are extremely sensitive to TNF and fail to induce MKP1. 
Whether the TA potential of GR is necessary for its antiinflamma-
tory activity is somewhat controversial. In this study, we investi-
gated whether the induction of GRE genes is necessary for the anti-
inflammatory functions counteracting TNF lethality. We injected 
WT control (GRwt/wt) and GRdim/dim mice i.p. with 25 μg TNF 
(a nonlethal dose for FVB/N mice) and monitored survival and 
body temperature. Mortality rate was significantly higher and 
hypothermia more pronounced in GRdim/dim than in GRwt/wt mice 
(Figure 1, A and B). Because IL-6 level is a good indicator of TNF 
sensitivity (26, 27), we measured IL-6 protein levels in circulation 
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0.5 hours after TNF stimulation. The significantly higher IL-6 levels in 
GRdim/dim mice (Figure 1C) confirmed their hypersensitivity to TNF. 
Furthermore, H&E staining of ileum samples showed that TNF 
treatment resulted in more severe intestinal damage in GRdim/dim 
than in GRwt/wt mice (Supplemental Figure 1A; supplemental mate-
rial available online with this article; doi:10.1172/JCI60006DS1). 
These data showed that dimerization of GR was essential for pro-
tection against TNF-induced shock, presumably by the induction 
of antiinflammatory GRE genes by endogenous GCs.
One of the most potent antiinflammatory genes induced by GR 
is Mkp1. To evaluate Mkp1 expression in our setting, GRwt/wt and 
GRdim/dim mice were injected i.p. with 500 μg of a synthetic GC, 
dexamethasone (DEX), or with PBS. Liver samples were isolated 
1 hour after DEX treatment, and mRNA expression of Mkp1 and 
Sgk1, a well-known GR dimer–dependent TA gene, was measured 
by quantitative real-time PCR (qPCR). DEX treatment of GRwt/wt 
mice resulted in a strong induction of Mkp1 and Sgk1 expression 
in liver; this induction was significantly weaker in GRdim/dim mice 
(Figure 1D). Because Mkp1 regulation by GCs is not restricted to 
the transcriptional level, MKP1 protein levels were also measured. 
MKP1 protein was induced after DEX injection only in GRwt/wt mice 
(Figure 1E), which indicates that the induction of both Mkp1 gene 
expression and MKP1 protein relies on GR dimerization. Since the 
regulation of MKP1 is controversial, we performed ChIP analysis to 
test whether the GR in GRdim/dim mice is indeed unable to bind to 
the GRE of the Mkp1 gene. GRwt/wt and GRdim/dim mice were injected 
i.p. with 500 μg DEX, and liver samples were isolated at time point 
0 or after 1 hour of DEX treatment. ChIP analysis was performed 
on these liver samples, and the isolated DNA was checked for Mkp1 
expression. The results showed that DEX treatment of GRwt/wt mice 
resulted in strong binding of GR to Mkp1 (Supplemental Figure 
1, B–E). This binding was substantially reduced in GRdim/dim mice, 
which indicates that the binding of GR to Mkp1 and subsequent 
induction of this gene indeed require GR dimerization.
Furthermore, as it is known that inflammatory stimuli can also 
induce Mkp1, most likely via the production of endogenous GCs, 
we investigated the induction of Mkp1 after TNF treatment. We 
injected GRwt/wt and GRdim/dim mice i.p. with 25 μg TNF and har-
vested liver samples after 0.5 hours. In GRwt/wt mice, TNF treatment 
resulted in the induction of Mkp1, whereas in GRdim/dim mice, this 
induction was significantly reduced (Figure 1F). These data indi-
cate that GR dimerization is necessary for the induction of Mkp1 
by DEX or by endogenous GCs induced by TNF. Taken together, 
our data demonstrated that dimerization of GR was indispensable 
for protection against TNF lethality. Furthermore, our findings 
provided evidence that Mkp1 is a GR dimer–dependent gene that 
might be involved in this protection against TNF.
Mkp1–/– mice are hypersensitive to TNF lethality. To examine whether 
MKP1 is indeed a critical player in the protection against TNF-
induced shock, we injected Mkp1+/+ and Mkp1–/– mice i.p. with 5 μg 
TNF, which is not lethal for normal C57BL6/J mice. Mortality rate 
was higher and hypothermia was more pronounced in Mkp1–/– than 
Figure 1
GRdim/dim mice are hypersensitive to TNF lethality and cannot induce MKP1. (A and B) Survival (A) and body temperature (B) of GRwt/wt (n = 7) and 
GRdim/dim (n = 9) mice after i.p. injection of 25 μg TNF. **P < 0.01, GRdim/dim vs. GRwt/wt. (C) IL-6 concentration in serum 0 and 0.5 hours after injec-
tion of 25 μg TNF (n = 5 per group). **P < 0.01, ***P < 0.001 vs. 0 hours; *P < 0.05 as indicated by brackets. (D) Mice were injected i.p. with PBS or 
500 μg DEX. 1 hour later, they were euthanized, and livers were harvested for qPCR analysis of Mkp1 and Sgk1 levels (n = 4 per group). (E) Mice 
were injected i.p. with PBS or 500 μg DEX. 1 hour later, mice were euthanized, and livers were harvested for ELISA of MKP1 protein levels (n = 6 
per group). (F) qPCR analysis of Mkp1 mRNA expression in livers of mice treated with 25 μg TNF for 0.5 hours (n = 5 per group). (D–F) *P < 0.05, 
**P < 0.01, ***P < 0.001 vs. PBS or as indicated by brackets. (A–F) Black bars and symbols, GRwt/wt; white bars and symbols, GRdim/dim.
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in Mkp1+/+ mice (Figure 2, A and B). These findings indicate that 
MKP1 plays a crucial role in controlling TNF lethality. To inves-
tigate the underlying mechanism, Mkp1+/+ and Mkp1–/– mice were 
injected i.p. with 5 μg TNF, and blood, liver, and ileum samples 
were obtained 0, 1, and 6 hours after TNF treatment. We measured 
IL-6 protein in circulation and Il6 gene expression levels in liver. 
TNF induced high levels of hepatic Il6 mRNA and serum IL-6 
protein 6 hours after TNF treatment, especially in Mkp1–/– mice 
(Figure 2C). Several other cytokines and chemokines in circula-
tion were also higher in Mkp1–/– than in Mkp1+/+ mice, especially 
6 hours after TNF treatment (Supplemental Figure 2). Addition-
ally, we tested the expression levels of different TNF-induced pro-
inflammatory genes in liver samples and in intestinal epithelial 
cells (IECs). Again, Mkp1–/– livers had significantly higher mRNA 
levels of Ccl5 (encoding CCL5 or RANTES), Timp1 (encoding the 
MMP inhibitor TIMP1) and Nos2 (encoding iNOS) 6 hours after 
TNF treatment (Figure 2, D and E). Strikingly, Mkp1–/– mice had 
significantly higher mRNA levels of these proinflammatory genes 
in IECs as early as 1 hour after TNF. These results indicated that 
MKP1 has an antiinflammatory effect that protects against TNF-
induced lethal inflammation.
As it was recently shown that MKP1 inhibits TNF-induced 
endothelial barrier dysfunction and apoptosis in HUVECs (28), and 
since TNF can cause intestinal damage and enterocyte apoptosis 
(5, 29), we investigated acute cell death in ileum samples of Mkp1+/+ 
and Mkp1–/– mice using H&E staining. As early as 1 hour after TNF 
challenge, the toxic effect of TNF was much more pronounced in 
Mkp1–/– than in Mkp1+/+ mice (Figure 2F). The intestinal damage 
was mainly characterized by loosening of the lamina propria, ero-
sion of the villi, and loss of goblet cells. The degree of intestinal 
damage was scored according to a previously published method 
(30). Intestines of Mkp1–/– mice were significantly more damaged 
than those of control Mkp1+/+ mice (Figure 2F). Furthermore, ileum 
samples were stained for active caspase 3 as a marker of apoptosis. 
In agreement with the H&E staining, we found significantly more 
cells expressing active caspase 3 in ileum samples of Mkp1–/– mice 
Figure 2
Mkp1–/– mice are hypersensitive to TNF-induced lethality. (A 
and B) Survival (A) and body temperature (B) of Mkp1+/+ (n = 12) 
and Mkp1–/– (n = 22) mice after injection of 5 μg TNF. *P < 0.05, 
***P < 0.001, Mkp1–/– vs. Mkp1+/+. (C) Serum IL-6 levels and liver Il6 
mRNA levels 0, 1, and 6 hours after 5 μg TNF (n = 5 per group). (D and 
E) Mice were injected i.p. with 5 μg TNF, and 0, 1, and 6 hours later, 
they were euthanized, and livers (D) and IECs (E) were isolated for 
qPCR analysis of Ccl5, Timp1 and Nos2 levels (n = 5 per group). (F) 
Standard H&E and active caspase 3 staining of ileum samples (n = 5 
per group). Representative images are shown. The ileum was sampled 
0 and 1 hour after injection of 5 μg TNF. The micrograph at the 0-hour 
time point is representative of both Mkp1+/+ and Mkp1–/– mice. Scale 
bars: 100 μm. Original magnification, ×40. (C–F) *P < 0.05, **P < 0.01, 
***P < 0.001 vs. 0 hours or as indicated by brackets. (G and H) Sur-
vival of Mkp1+/+ (G) and Mkp1–/– (H) mice pretreated with 10 mg/kg 
DEX (squares; n = 8 per group) or solvent (circles; n = 8 [Mkp1+/+]; 
7 [Mkp1–/–]) and injected with 15 μg (G) or 7.5 μg (H) TNF. **P < 0.01, 
DEX vs. solvent. (A–H) Black bars and symbols, Mkp1+/+; white bars 
and symbols, Mkp1–/–.
Figure 3
JNK phosphorylation in liver is higher in 
Mkp1–/– and GRdim/dim mice. (A) Western 
blot analysis of phospho-JNK1/2 protein 
levels in livers of Mkp1+/+ and Mkp1–/– mice. 
Mice were injected i.p. with 5 μg TNF, and 
livers were harvested at the indicated times 
after challenge. The phospho-JNK1/2 
bands (46 kDa and 54 kDa) were normal-
ized to the intensities of the total JNK1/2 
and actin bands (42 kDa). Black bars, 
Mkp1+/+; white bars, Mkp1–/–. (B) Western 
blot analysis of phospho-JNK1/2 protein 
levels in livers of GRwt/wt and GRdim/dim 
mice. Mice were treated with 25 μg TNF; 
0 and 0.5 hours later, they were euthanized, 
and livers were obtained for Western blot 
analysis. Normalized values are also 
shown. Black bars, GRwt/wt; white bars, 
GRdim/dim. (A and B) *P < 0.05, **P < 0.01, 
***P < 0.001 vs. 0 hours or as indicated by 
brackets. See complete unedited blots in 
the supplemental material.
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(Figure 2F). These data indicate that within 1 hour after TNF treat-
ment, Mkp1–/– mouse intestine is severely damaged because of a 
high rate of apoptosis combined with severe inflammation.
Additionally, to investigate whether GC inhibition of the response 
to TNF occurs through MKP1, we examined whether pretreating 
Mkp1–/– mice with endogenous GCs can protect against TNF-
induced lethal shock. We injected the mice with 10 mg/kg DEX 
and 0.5 hours later with LD80 of TNF (15 μg for Mkp1+/+; 7.5 μg 
for Mkp1–/–). In keeping with previous reports by our group (7, 9), 
Mkp1+/+ mice were protected against TNF by pretreatment with DEX 
compared with mice pretreated with diluted methanol solvent (90% 
vs. 10% survival; Figure 2G). However, pretreatment of Mkp1–/– mice 
with DEX or solvent failed to protect them against TNF lethality 
(10% survival; Figure 2H). These data demonstrated that MKP1 was 
indispensable in the protective action of GCs against TNF.
Prolonged JNK activation in Mkp1–/– and GRdim/dim mice. MKP1 is 
known to dephosphorylate and hence inactivate MAPKs, particu-
larly JNK and p38, but also ERK (16). As MAPKs are activated by 
TNF and mediate part of the TNF proinflammatory induction 
profile (31), we examined the status of activated MAPKs in liver 
samples of Mkp1+/+ and Mkp1–/– mice. Both mouse groups were 
injected i.p. with 5 μg TNF and sacrificed at time point 0 or after 
10 minutes or 0.5, 1, or 2 hours, and hepatic MAPK levels were 
examined. We observed rapid induction of phospho-JNK1/2 10 
minutes after TNF injection in both Mkp1+/+ and Mkp1–/– mice 
(Figure 3A). This induction declined rapidly in Mkp1+/+ mice, 
starting 0.5 hours after TNF injection, when phospho-JNK1/2 
levels in Mkp1–/– mice were still increasing (Figure 3A and Supple-
mental Figure 3). These data indicate that TNF treatment results 
in prolonged activation of JNK1/2 in Mkp1–/– compared with 
Mkp1+/+ mice. Levels of phospho-ERK and phospho-p38 were also 
examined, but no differences between Mkp1+/+ and Mkp1–/– mice 
were observed (Supplemental Figure 4, A and B).
Because GRdim/dim mice were very sensitive to TNF and had weaker 
induction of MKP1, it is conceivable that these mice also display 
stronger activation of JNK1/2 upon TNF challenge. Therefore, we 
evaluated phospho-JNK1/2 levels 0.5 hours after TNF challenge in 
GRwt/wt and GRdim/dim mice. Interestingly, activation of JNK1/2 was 
stronger in GRdim/dim mice (Figure 3B), as was observed in Mkp1–/– 
mice. These observations indicated that activation of JNK1/2 is 
stronger in Mkp1–/– and GRdim/dim mice.
JNK2, not JNK1, is an essential mediator of TNF-induced lethality. 
Because phospho-JNK1/2 levels were significantly higher in liv-
ers of Mkp1–/– and GRdim/dim mice than in their WT controls, we 
studied the response of JNK-deficient mice to TNF. WT control, 
Jnk1–/–, and Jnk2–/– mice were injected i.p. with 10 μg TNF (an LD50 
dose for C57BL/6 mice), and survival and body temperature were 
monitored. Although Jnk1–/– mice showed no change in sensitiv-
ity to TNF, Jnk2–/– mice were significantly more protected against 
TNF than control mice, as shown by the significantly lower mor-
tality rate and less severe hypothermia (Figure 4, A and B). These 
findings indicated that JNK2, but not JNK1, is an essential media-
tor of TNF-induced lethal shock.
Furthermore, control and Jnk2–/– mice were injected i.p. with 10 μg 
TNF, and blood, liver, and ileum samples were harvested 0, 1, and 
6 hours later. IL-6 protein and Il6 mRNA levels, cytokine and che-
mokine levels in circulation, and proinflammatory gene expression 
levels in liver clearly demonstrated that Jnk2–/– mice were protected 
against TNF-induced inflammation, especially at the later 6-hour 
time point (Figure 4, C and D, and Supplemental Figure 5). Togeth-
er, these data indicated that JNK2 has a proinflammatory role.
Moreover, measuring proinflammatory gene expression levels in 
IECs and stainings of ileum samples with H&E and for active cas-
pase 3 showed that inflammatory state, tissue damage, and acute 
cell death 1 hour after TNF injection was much more pronounced 
in the intestine of Jnk2+/+ than in Jnk2–/– mice (Figure 4, E and F). 
As these characteristics were absent in Jnk2–/– mice, we hypothe-
sized that JNK2 might be the mediator of TNF-induced intestinal 
permeability. We therefore injected Jnk2+/+ and Jnk2–/– mice with 
10 μg TNF, followed 3 hours later by oral administration of 25 
mg/ml FITC-dextran. Blood samples were collected 8 hours after 
TNF challenge, and plasma was tested for FITC signal. Jnk2+/+ mice 
showed a stronger signal than Jnk2–/– mice (Figure 4G), which indi-
cates that TNF induced more intestinal permeability in the Jnk2–/– 
mouse. Taken together, these observations indicated that the 
effects of TNF on the epithelium (i.e., induction of inflammation 
and apoptosis) started very early, by 1 hour after TNF. Increased 
inflammation in liver and circulation seemed to be secondary to 
intestinal damage, as shown by the defect in intestinal permeabil-
ity. Additionally, our findings provided evidence that JNK2 is a 
critical mediator of these TNF effects.
Mkp1–/–Jnk2–/– and GRdim/dimJnk2–/– mice are less sensitive to TNF. 
Since Mkp1–/– mice were very sensitive to the in vivo effects of TNF, 
and since MKP1 also dephosphorylated JNK1/2 in the TNF model, 
we wondered whether the sensitivity of Mkp1–/– mice to TNF is due 
to overactive JNK kinases. To test this hypothesis, we generated 
Mkp1–/–Jnk2–/– mice and studied their sensitivity to TNF. Control 
Mkp1+/+Jnk2+/+, Mkp1–/–, and Mkp1–/–Jnk2–/– mice were injected i.p. 
with 5 μg TNF (which is lethal for Mkp1–/– mice), and mortality 
and body temperature were monitored. The sensitivity of Mkp1–/– 
Jnk2–/– mice to TNF was intermediate between that of Mkp1+/+ 
Jnk2+/+ and Mkp1–/– mice (Figure 5, A and B), which suggests that 
Jnk2 rescues TNF sensitivity, at least in part, in Mkp1–/– mice. The 
intermediate sensitivity of Mkp1–/–Jnk2–/– mice was confirmed by 
measuring IL-6 protein in circulation and Il6 mRNA in liver (Fig-
ure 5C). Furthermore, H&E staining of ileum samples 1 hour after 
TNF injection showed that intestinal damage was comparable 
in Mkp1+/+Jnk2+/+ and Mkp1–/–Jnk2–/– mice, but much more pro-
nounced in Mkp1–/– mice (Figure 5D). These observations indicate 
that Mkp1–/–Jnk2–/– mice are much less sensitive to TNF than are 
Mkp1–/– mice, which indicates that the sensitivity of Mkp1–/– mice 
Figure 4
Jnk2–/– mice are resistant to TNF-induced shock. (A) Survival of control 
(black squares; n = 19), Jnk2–/– (white squares; n = 12), and Jnk1–/– 
(gray circles; n = 6) mice after i.p. injection of 10 μg TNF. **P < 0.01 vs. 
control. (B) Body temperature of control (n = 12), Jnk2–/– (n = 12), and 
Jnk1–/– (n = 6) mice after injection of 10 μg TNF. *P < 0.05. (C) Serum 
IL-6 levels and liver Il6 mRNA levels 0, 1, and 6 hours after challenge 
with 10 μg TNF (n = 5 per group). (D and E) Mice were injected i.p. with 
10 μg TNF; 0, 1, and 6 hours later, they were euthanized, and livers 
(D) and IECs (E) were obtained for qPCR analysis of Ccl5, Timp1, and 
Nos2 levels (n = 5 per group). (F) Standard H&E and active caspase 
3 staining of ileum samples (n = 5 per group). Representative images 
are shown. The ileum was sampled 0 and 1 hours after TNF injec-
tion. The micrograph at 0 hours is representative of both control and 
Jnk2–/– mice. Scale bars: 100 μm. Original magnification, ×40. (C–F) 
*P < 0.05, **P < 0.01, #P < 0.001 vs. 0 hours or as indicated by brack-
ets. (G) Relative permeability 8 hours after injection of 10 μg TNF or 
PBS. **P < 0.01. (B–G) Black bars and symbols, control; white bars 
and symbols, Jnk2–/–; gray bars and symbols, Jnk1–/–.
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can be partly rescued by specifically inhibiting JNK2. We therefore 
conclude that JNK2 is one of the critical players responsible for the 
increased sensitivity of Mkp1–/– mice to TNF.
Furthermore, we assessed the response of GRdim/dimJnk2–/– mice 
to shock. Control GRwt/wtJnk2+/+, GRdim/dim, and GRdim/dimJnk2–/– 
mice were injected i.p. with 20 μg TNF (which is lethal for GRdim/dim 
mice with a mixed C57BL/6-FvB background), and mortality and 
body temperature were monitored. The sensitivity of GRdim/dim 
Jnk2–/– mice was intermediate between those of GRwt/wtJnk2+/+ and 
GRdim/dim mice (Figure 5, E and F). These results suggest that JNK2, 
at least in part, rescues the sensitivity of GRdim/dim mice to TNF, as 
it did in Mkp1–/–Jnk2–/– mice. Taken together, these data indicate 
that dimerized GR protects against TNF-induced shock by induc-
tion of MKP1 and subsequent inhibition of JNK2.
Discussion
TNF is a pleiotropic cytokine with strong proinflammatory capac-
ity, and it is a well validated drug target in several inflammatory dis-
orders, such as rheumatoid arthritis, IBD, and psoriasis (1, 2). How-
ever, the use of biological drugs inhibiting TNF is very expensive and 
can result in unwanted side effects, such as tuberculosis (3).
It has been known for a long time that GCs protect against TNF-
induced lethal shock and that this protection is mediated by binding 
of GCs to GR, a very potent antiinflammatory protein (7). However, 
therapy with GCs can also induce side effects, such as diabetes. It is 
believed that the side effects are induced by TA, whereas the antiin-
flammatory effects are mainly attributable to the TR actions of GR.
Most studies claim that interaction of monomeric GR with tran-
scription factors forms the basis for its antiinflammatory activ-
Figure 5
Mkp1–/–Jnk2–/– mice show reduced sensitivity to TNF. (A) Survival of Mkp1+/+Jnk2+/+ (black squares; n = 22), Mkp1–/– (gray circles; n = 34), and 
Mkp1–/–Jnk2–/– (white squares; n = 24) mice after i.p. injection of 5 μg TNF. *P < 0.05, ***P < 0.001 vs. control; **P < 0.01, Mkp1–/–Jnk2–/– vs. 
Mkp1–/–. (B) Body temperature of mice as in A. **P < 0.01, ***P < 0.001. (C) Serum IL-6 concentrations and liver Il6 mRNA levels 0, 1, and 
6 hours after challenge with 5 μg TNF (n = 5 per group). (D) Standard H&E staining of ileum samples (n = 5 per group). The ileum was sampled 
0 and 1 hour after i.p. injection of 5 μg TNF. The micrograph at 0 hour is representative of all genotypes. Scale bars: 100 μm. Original magnifica-
tion, ×40. (C and D) *P < 0.05, **P < 0.01, ***P < 0.001 vs. 0 hours or as indicated by brackets. (B–D) Black bars, Mkp1+/+Jnk2+/+; white bars, 
Mkp1–/–Jnk2–/–; gray bars, Mkp1–/–. (E and F) Survival (E) and body temperature (F) of GRwt/wtJnk2+/+ (black bars and symbols; n = 7), GRdim/dim 
(gray bars and gray circles; n = 5), and GRdim/dimJnk2–/– (white bars and white squares; n = 3) mice after i.p. injection of 20 μg TNF. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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ity (32). Hence, the research community is currently investigating 
the development of GR ligands that favor TR. However, whether 
the TA potential of GR is also required for its antiinflammatory 
capacity remains unclear. Some studies have provided evidence 
that induction of antiinflammatory genes by GR dimers is indis-
pensable for the antiinflammatory effects of GR (23). Indeed, sev-
eral TA genes, such as Mkp1, have antiinflammatory activity. This 
has been demonstrated by many studies using Mkp1–/– mice in sev-
eral sepsis models, such as LPS administration, cecal ligation and 
puncture, and colon ascendens stent peritonitis, as well as in other 
disease models, such as collagen-induced arthritis (17–19).
To examine to which extent GR dimerization–dependent TA is 
required for protection against TNF, we tested the sensitivity of 
GRdim/dim mice to TNF. These mice express a GR molecule that can-
not form GR dimers and predominantly results in TR. We demon-
strated that injection of TNF in GRdim/dim mice caused a height-
ened sensitivity to its toxic effects compared with GRwt/wt mice. We 
concluded that GR dimerization was indispensable for the protec-
tion provided by endogenous GCs against the acute inflammatory 
and lethal effects of TNF. The toxic effects of TNF were initiated 
early and resulted in severe hypothermia, high levels of circulat-
ing IL-6, intestinal damage, and subsequent high mortality. All 
these characteristics were substantially greater in GRdim/dim than 
in GRwt/wt mice. Furthermore, we demonstrated that GRdim/dim 
mice did not induce expression of Mkp1 after treatment with DEX 
or TNF, which suggests that Mkp1 might play a role in the protec-
tion against TNF. Several studies have shown that MKP1 protein 
levels parallel mRNA levels. Valledor et al. showed that synthesis 
of MKP1 protein is tightly correlated with the time course of Mkp1 
mRNA expression in LPS-treated macrophages (33). MKP1 pro-
tein levels were also found to follow the same pattern of induc-
tion as Mkp1 mRNA in H2O2-treated HeLa cells (34). We also 
measured MKP1 protein levels in our model, and our data showed 
that MKP1 protein levels indeed followed Mkp1 mRNA expression 
levels. Thus, the induction of Mkp1 mRNA expression and MKP1 
protein levels both relied on GR dimerization.
The regulation of MKP1 is of much interest, but remains contro-
versial. Recently, ChIP sequencing studies revealed a GRE site in 
the promoter region of Mkp1 (35, 36). Furthermore, it was shown 
that DEX treatment leading to Mkp1 induction in liver and in vari-
ous other cell types is dependent on GR dimerization (37). This 
was confirmed by our ChIP results, which indicated that binding 
of GR to Mkp1 and subsequent Mkp1 induction required GR dimer-
ization. However, this was at odds with previous findings showing 
that in GRdim/dim macrophages, Mkp1 can still be induced by DEX 
(17). Tissue specificity could be the reason for this discrepancy.
The prominent role of Mkp1 in the control of the excessive 
inflammation induced by TNF was confirmed in Mkp1–/– mice, 
which were extremely sensitive to TNF compared with Mkp1+/+ 
mice. These findings correlated with the antiinflammatory effects 
of MKP1 described in other inflammation models (17–19).
TNF has previously been shown to mediate disruption of the 
intestinal mucosal barrier, which is followed by translocation of 
invasive bacteria into the blood stream after endotoxemia (38, 39). 
The present study showed that TNF resulted in intestinal dam-
age and inflammation and disruption of the intestinal barrier 
as early as 1 hour after TNF challenge, and systemic inflamma-
tion followed later, at the 6-hour time point. This inflammation 
was characterized by high levels of circulating chemokines and 
cytokines and high expression levels of proinflammatory genes in 
the liver. Moreover, this cascade of inflammation and apoptosis in 
the gut followed by systemic inflammation was tightly regulated 
by MKP1, as Mkp1–/– mice were hypersensitive to TNF-mediated 
apoptosis, inflammation, and subsequent lethality.
It was crucial to show that GCs did not protect against TNF-
induced shock in Mkp1–/– mice. A functional Mkp1 gene is probably 
required for maximal protective effects, as previously shown for 
DEX protection against endotoxic shock (40). In that study, DEX 
only partially protected Mkp1–/– mice from endotoxic shock, where-
as WT mice were completely protected from endotoxin-induced 
mortality. Our present results indicated that DEX pretreatment, in 
the absence of MKP1, did not fully protect Mkp1–/– mice from the 
lethal effect of TNF. Thus, MKP1 was required for the protection 
provided by GCs against TNF. However, TNF-induced mortality 
was somehow delayed in DEX- versus solvent-treated Mkp1–/– mice. 
Despite the essential role of MKP1 in the protective effects of GCs 
in several inflammatory models, including our TNF model, some 
GC effects occur independently of MKP1. GCs might have some 
direct antiinflammatory effects, or they might also act via the 
induction of other antiinflammatory proteins. This idea is sup-
ported by the prior finding that inhibition of protein synthesis in 
bone marrow–derived mast cells from Mkp1–/– mice partly reverses 
the antiinflammatory effects of GCs (41).
In keeping with the well-known dephosphorylation actions of 
MKP1, we showed here that Mkp1–/– mice exhibited prolonged 
Figure 6
JNK2 is an essential player in TNF lethality, leading to cell death, bowel 
damage, intestinal inflammation, systemic inflammation, and conse-
quent death. In GRwt/wt mice, TNF can induce Mkp1 via GR dimers. 
Mkp1 dephosphorylates JNK2 and hence inhibits its activity. In GRdim/dim 
mice, TNF fails to induce Mkp1. These mice show prolonged and 
higher activation of JNK2, which results in a higher sensitivity to TNF-
induced lethal shock. Dashed lines indicate the possible involvement 
of other MKP1 targets in the TNF pathway.
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JNK1/2 phosphorylation. Moreover, GRdim/dim mice had higher lev-
els of phospho-JNK1/2. To determine whether increased JNK acti-
vation indeed forms the basis of the hypersensitivity of Mkp1–/– and 
GRdim/dim mice to TNF, we studied the effects of TNF in Jnk1–/– and 
Jnk2–/– mice. We found that Jnk2–/– mice, but not Jnk1–/– mice, were 
resistant to TNF. The absence of JNK2 led to resistance against 
very early TNF-induced gut epithelial cell death, intestinal inflam-
mation, and intestinal permeability as well as against subsequent 
systemic inflammation. We previously demonstrated that bowel 
damage is a very fast and essential step in TNF-induced lethal 
inflammation (42, 43), and other groups have shown that TNF 
mediates gut epithelial cell death in genetic mouse models of IBD, 
such as in the IKKγ knockout mouse (44). JNK molecules have been 
shown to mediate the apoptosis activity of TNF (45, 46), and JNK2 
has been shown to induce apoptosis by regulating both mitochon-
drial and lysosomal death pathways (24, 25). Furthermore, several 
studies have indicated a role for JNK in regulating apoptosis in 
IECs (47, 48). Additionally, Ray et al. showed increased levels of 
both phospho-JNK1 and phospho-JNK2 in IEC-6 cells upon TNF 
challenge when the cells were also treated with MKP1 siRNA (48). 
That JNK increase subsequently resulted in more apoptosis in 
these cells, mediated by activated caspase 9 and caspase 3. Phos-
pho-JNK1/2 levels were induced in IEC-6 cells within 15 minutes 
of TNF treatment and declined after 1 hour. This is in accordance 
with our present results using liver samples.
Here, we provided evidence that JNK2, but not JNK1, was an 
essential player in mediating apoptosis of IECs in response to 
TNF. We therefore conclude that JNK2 is a critical mediator of 
TNF lethality. Our data support the idea that JNK2 plays an essen-
tial role in the in vivo effects of TNF by mediating early cell death 
of IECs, which leads to disruption of the intestinal barrier and 
consequent systemic inflammation.
Since Mkp1–/–Jnk2–/– and GRdim/dimJnk2–/– mice were significantly 
less sensitive to TNF than were Mkp1–/– and GRdim/dim mice, respec-
tively, the hypersensitivity of Mkp1–/– and GRdim/dim mice was largely 
due to JNK2. Since Mkp1–/–Jnk2–/– mice did show the same extent 
of intestinal damage as control mice, JNK2 seemed to be critical 
for induction of intestinal damage. This is confirmed by another 
study showing that JNK mediates apoptosis of IECs (48). Further-
more, the authors show that knockdown of MKP1 in IECs by using 
siRNA enhances the activity of JNK and increases subsequent 
apoptosis. However, in our study, the response to TNF in Mkp1–/–
Jnk2–/– mice was intermediate between those of Mkp1+/+Jnk2–/– and 
Mkp1–/– mice. Thus, it is likely that the TNF pathway involves other 
players contributing to its lethal effects, especially its inflamma-
tory effects, such as MAPK p38 and ERK. p38 in particular seems 
to be an excellent candidate, because the substrate specificity of 
MKP1 is greater for p38 and JNK than for ERK (18, 19). Moreover, 
several studies have proven an important role for p38 in mediating 
acute inflammation, such as the successful use of a MAPK inhibi-
tor in vivo by Bhattacharyya et al. (49). These authors showed that 
a specific p38 inhibitor protected macrophage-specific GR–/– mice 
from LPS lethality attributed to impaired induction of MKP1. 
Furthermore, a critical role for p38 and subsequent NF-κB activa-
tion was recently described in several reports. It was shown that 
curcumin, which has antiinflammatory and antioxidant activities, 
protects the intestinal mucosal barrier by induction of MKP1 and 
subsequent inactivation of p38 and of NF-κB–mediated transcrip-
tion (50). In addition, some reports suggest that ERK could be an 
important mediator of TNF-induced shock and provide a link 
with MKP1 (51, 52). However, because we observed identical phos-
pho-p38 and phospho-ERK levels in Mkp1+/+ and Mkp1–/– mice, the 
contribution of these MAPKs in the context of the present study 
can be ruled out. It is probable that other yet-unidentified targets 
of MKP1 could account for the TNF-induced toxic effects. Taken 
together, our results suggest that by limiting the duration of JNK2 
activity, MKP1 provides a crucial negative feedback mechanism of 
GCs during inflammatory responses.
In summary, we showed that dimerization of GR was essential 
for protection against acute TNF-mediated inflammation and 
critical for Mkp1 induction, and hence controlled activation of the 
proapoptotic JNK2. Our observations suggest that JNK2 mediates 
TNF lethality by inducing intestinal apoptosis and inflammation 
as well as subsequent systemic inflammation (Figure 6). To our 
knowledge, this is the first in vivo evidence that GR dimerization 
is important in the regulation of TNF-induced apoptosis.
Another important conclusion of our work is that both anti-
apoptotic and antiinflammatory effects of GCs necessitate the 
induction of gene expression and require GR dimerization. Thus, 
the dissociation model calling for prevention of GR-induced gene 
induction and stimulation of GR transrepression by synthetic GR 
ligands (i.e., selective GR agonists [SEGRAs]), although attrac-
tive, has some limitations, at least in this type of acute inflamma-
tion. Especially in acute inflammatory settings, GR-induced gene 
expression makes a major contribution to protection, and hence 
inhibition of GR dimerization might be dangerous.
Methods
Mice. C57BL6/J mice were purchased from Janvier. GRdim mice were gen-
erated by Reichardt et al. (21) and backcrossed on a FVB/N background. 
Heterozygous GRdim mice were intercrossed to generate GRdim/dim homo-
zygous mutant mice and GRwt/wt homozygous WT mice. Mkp1–/– mice 
had a C57BL6/J background and were generated by Bravo et al. (53) and 
provided by Y. Liu (Ohio State University, Columbus, Ohio, USA). Jnk1–/– 
and Jnk2–/– mice had a C57BL6/J background and were purchased from 
The Jackson Laboratories. Pure C57BL6/J mice were used as controls for 
Mkp1–/–, Jnk1–/–, and Jnk2–/– mice. In order to generate Mkp1–/–Jnk2–/– and 
GRdim/dimJnk2–/– mice, single knockouts were crossed, and F1 hybrids were 
intercrossed to yield double-WT Mkp1+/+Jnk2+/+ and GRwt/wtJnk2+/+ mice and 
double-deficient Mkp1–/–Jnk2–/– and GRdim/dimJnk2–/– mice. All offspring 
were genotyped by PCR on genomic DNA isolated from tail biopsies. The 
mice were kept in individually ventilated cages under a 12-hour dark/ 
12-hour light cycle in a conventional animal house and received food and 
water ad libitum. All mice were used at 8–12 weeks of age.
Reagents. Recombinant mouse TNF was produced in E. coli and purified 
to homogeneity in our laboratories. TNF had a specific activity of 1.2 × 108 
IU/mg and no detectable endotoxin contamination.
Injections and sampling. TNF was diluted in pyrogen-free PBS. All injections 
were given i.p. Blood was withdrawn with a glass capillary from the retroor-
bital plexus and allowed to clot overnight at 4°C. The clot was then removed, 
and serum was collected after centrifugation at 20,000 g for 10 minutes and 
stored at –20°C. For sampling liver tissue, mice were killed by cervical dis-
location, and tissue samples were fixed briefly in 4% paraformaldehyde and 
embedded in paraffin by a standard protocol (Tissue-Tek VIP; Sakura). A 
piece of liver was stored in RNA later (Qiagen) for RNA preparation, and the 
rest was snap-frozen in liquid nitrogen and stored at –80°C.
Measurements of cytokines in circulation. Serum IL-6 was determined 
with a 7TD1 bioassay (54). Serum samples were also assayed for several 
cytokines using Luminex technology (Bio-Rad, Nazareth-Eke) following 
the manufacturer’s protocol.
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Tissue section, histology, and immunohistochemistry. Tissue sections of 4 μm 
were cut and stained with H&E using standard techniques. After stain-
ing, the labels on the bowel sections were blinded, and tissue damage was 
quantified by 4 neutral observers using the necrotizing enterocolitis scor-
ing system published and validated by Halpern et al. (30). The mean value 
of their estimations was used. For caspase 3 staining, 4-μm sections were 
deparaffinized for antigen retrieval (target retrieval solution; Dako) and 
then rehydrated. For visualization, we used an antibody against active 
caspase 3 (APO active 3 antibody specific active caspase 3 detection Kit 
[PE]; Cell Technology), EnVision+ HRP (Dako), and DAB (Dako). The 
slides were counterstained with hematoxylin solution (Mayer) and dehy-
drated. Caspase 3–positive cells were counted in 5 random ×40 fields in 
a double-blinded fashion. Negative controls were made by substituting 
buffer for primary antibody.
qPCR analysis. Tissue samples were collected in RNA later (Qiagen), and 
RNA was isolated with the RNeasy Mini kit (Qiagen) according to the man-
ufacturer’s instructions. RNA concentration was measured with Nanodrop 
1000 (Thermo Scientific), and 1 μg RNA was used to prepare cDNA with 
Superscript II (Invitrogen). qPCR was performed using the Roche Light-
Cycler 480 system (Applied Biosystems). The best-performing housekeeping 
genes were determined by Genorm (55). Results are given as relative expres-
sion values normalized to the geometric mean of the housekeeping genes.
MKP1 ELISA. Protein was extracted from liver samples by homogeniz-
ing tissue in 0.5% CHAPS lysis buffer containing protease inhibitors. The 
supernatant was stored at –70°C. Intestinal MKP1 was measured using a 
commercially available ELISA assay (USCNK Life Sciences Inc.).
Western blot analysis. Whole tissue lysates containing 100 μg protein 
were separated by electrophoresis in a 10% gradient SDS-polyacrylamide 
gel and transferred to nitrocellulose filters. The membranes were incu-
bated overnight at 4°C with primary antibodies against phospho-JNK1/2 
(1:1,000; catalog no. 9910s, Cell Signaling) and total JNK (1:1,000; cata-
log no. 554285, BD Biosciences — Pharmingen), phospho-p38 (1:1,000; 
catalog no. 9910s, Cell Signaling), phospho-ERK1/2 (1:1,000; catalog no. 
9910s, Cell Signaling), and actin (1:10,000; MP Biomedicals) as an inter-
nal control. Blots were washed with Tris-buffered saline containing 0.1% 
Tween20, then incubated for 1 hour at room temperature with anti-rabbit 
antibody (1:10,000; catalog no. 926-32211, Li-cor) and anti-mouse anti-
body (1:15,000; catalog no. 926-32220, Li-cor). Immunoreactive bands 
were detected using the Odyssey Infrared Imager (Li-cor) and quantified 
using Odyssey Application software (version 2.1, Li-cor).
ChIP. Liver samples were homogenized in cold PBS and crosslinked 
in 2% paraformaldehyde for 10 minutes at room temperature. The reac-
tion was stopped with 1 M glycine. Liver lysates were sonicated and then 
subjected to IP with rabbit anti-GR antibody (5 μg per IP; catalog no. 
sc8992, Santa Cruz Biotechnology). The material was decrosslinked by 
raising the incubation temperature to 65°C for 16 hours. The recovered 
DNA was purified by the PCR purification kit (Qiagen). qPCR was per-
formed using the Roche LightCycler 480 system (Applied Biosystems). 
Mkp1 primer pairs were as follows (based on ref. 56): MKP1-1 (1.3), 
5ʹ-CAAGAGCTAAGAGAGGCCAAA-3ʹ and 5ʹ-CACGGAGTTGGATA-
CACAAACA-3ʹ; MKP1-2 (2.4), 5ʹ-GTGCCTGGCTCTGCATCGAAAAT-
GGAA-3ʹ and 5ʹ-TGGCTCAGACACTGCTGTCCCCTCT-3ʹ; MKP1-3 
(2.8), 5ʹ-GCTTCCCAGATGTGCCAAG-3ʹ and 5ʹ-CCAAACCTTGAGC-
CAGAGCAGTG-3ʹ; MKP1-4 (2.9), 5ʹ-CTTAGGGTGAACTGACATC-3ʹ 
and 5ʹ-CTTTGAGCTCACTTCCTGTTTTGTG-3ʹ.
Intestinal permeability. Animals underwent an in vivo intestinal perme-
ability assay at 8 hours after TNF treatment using methods described pre-
viously (57). At 3 hours after TNF, 200 μl FITC-dextran (25 mg 4.4-kDa 
FITC-dextran in 1 ml PBS) was administered orally. At 8 hours after TNF, 
blood was collected into heparinized Eppendorf tubes and centrifuged at 
10,000 g for 10 minutes. Plasma was collected and subsequently assayed for 
concentration of FITC-dextran.
Statistics. Survival curves (Kaplan-Meyer plots) were compared by log-
rank test, and final outcomes by χ2 test. Statistical significance of dif-
ferences between groups was evaluated by 2-tailed Student’s t tests with 
95% confidence intervals and by 2-way ANOVA. All data are expressed as 
mean ± SEM. P values less than 0.05 were considered significant.
Study approval. All animal experiments were approved by the institu-
tional ethics committee for animal welfare of the Faculty of Sciences, 
Ghent University.
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